Method
We are conducting a dose-escalating study of AD-p53 given to patients with locally advanced prostate cancer. One course of gene therapy consists of three separate administrations of AD-p53 (3 ml total delivered dose, given in four to six divided injections) by intraprostatic transrectal ultrasound-guided injections every 14 days.
Results
To date, 17 patients have received the intraprostatic injections and 14 have completed AD-p53 therapy and undergone radical prostatecomy. Three patients completed two courses of therapy because they had a clinical tumour size reduction greater than 25% (as shown by magnetic resonance imaging). There were no grade 3 or 4 toxic effects in the 14 patients who could be evaluated. One patient was hospitalized for postoperative pelvic discomfort. Five patients have reached the maximum tolerated dose (3 6 10 12 viral particles), with grade 1 fever being the predominant side-effect.
Conclusion
The ®rst 17 patients have tolerated the intraprostatic ADp53 therapy well. The dose±response curve, degree of transgene expression and induction of apoptosis have not yet been fully determined. The relationship between radiographic response and pathologic ®ndings of disease will also be determined. The results of this trial will form the basis of combination therapy and establish the methodology for intraprostatic therapy.
